Table I.
Major characteristics of the patients with metastatic breast cancer from the present cohort study (n=166).
| Main characteristics | HR+/HER2− (n=92) | HR+/HER2+ (n=26) | HR-/HER2+ (n=21) | HR-/HER2- (n=27) |
|---|---|---|---|---|
| Age (years) | ||||
| <40 | 19 (20.6) | 5 (19.2) | 2 (9.5) | 1 (3.7) |
| 40-49 | 26 (28.3) | 8 (30.8) | 3 (14.3) | 9 (33.3) |
| 50-59 | 26 (28.3) | 6 (23.1) | 9 (42.9) | 11 (40.8) |
| ≥60 | 21 (22.8) | 7 (26.9) | 7 (33.3) | 6 (22.2) |
| Menopausal status | ||||
| Premenopause | 41 (44.6) | 12 (46.2) | 5 (23.8) | 9 (33.3) |
| Postmenopause | 51 (55.4) | 14 (53.8) | 16 (76.2) | 18 (66.7) |
| Tumor stage | ||||
| T1 | 9 (9.8) | 5 (19.2) | 4 (19.1) | 8 (29.6) |
| T2 | 55 (59.8) | 11 (42.3) | 8 (38.1) | 15 (55.6) |
| T3 | 18 (19.6) | 9 (34.6) | 7 (33.3) | 3 (11.1) |
| T4 | 10 (10.8) | 1 (3.9) | 2 (9.5) | 1 (3.7) |
| TNM stage | ||||
| I | 7 (7.6) | 4 (15.4) | 0 (0) | 3 (11.1) |
| II | 34 (37.0) | 7 (26.9) | 6 (28.6) | 12 (44.4) |
| III | 51 (55.4) | 15 (57.7) | 15 (71.4) | 12 (44.4) |
| Lymph node status | ||||
| Positive | 65 (70.7) | 19 (73.1) | 19 (90.5) | 16 (59.3) |
| Negative | 27 (29.3) | 7 (26.9) | 2 (9.5) | 11 (40.7) |
| Histopathological type | ||||
| Invasive ductal carcinoma | 75 (81.5) | 23 (88.5) | 18 (85.7) | 25 (92.6) |
| Invasive lobular carcinoma | 4 (4.3) | 0 (0) | 0 (0) | 1 (3.7) |
| Ductal carcinoma in situ | 2 (2.2) | 2 (7.7) | 1 (4.8) | 0 (0) |
| Other | 11 (12.0) | 1 (3.8) | 2 (9.5) | 1 (3.7) |
Values are expressed as n (%). HR, hormone receptor; HER2, human epidermal growth factor receptor 2.